immuno-oncology

News

Keytruda backed by NICE for late-stage oesophageal cancer

MSD's Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making it an option for routine NHS treatment.

News

First FDA filing for Novartis' latecomer PD-1 drug tislelizu...

Novartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier this year – as a sec

News

Roche dives further into cancer cell therapy with Adaptimmun...

Roche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for cancer, but it has made a big play now, pledging $150 million upfront to an allianc

R&D

Targeting COVID-19 and cancer with immunotherapy advancement...

Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform.

News

Novartis' bid to extend Kymriah into earlier use hits a road...

Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

News